FranceMed Pharma Ltd. of London at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair
Manufacturers Trader

FranceMed Pharma Ltd.

27 Old Gloucester Street, WC1N 3AX London
United Kingdom of Great Britain and Northern Ireland

Telephone +44 208 6450773
Fax +44 208 6450822
info@francemedpharma.com

This company is co-exhibitor of
ABHI Association of British Healthcare Industries Ltd.

Hall map

MEDICA 2017 hall map (Hall 16): stand F20-2

Fairground map

MEDICA 2017 fairground map: Hall 16

Contact

Mark Taylor

Our range of products

Product categories

  • 05  Commodities and Consumer Goods
  • 05.02  Universal medical commodities

Our products

Product category: Universal medical commodities

Our products

Therapeutic/ OTC Micro-fine sprays to treat conditions in: Dermatology, Gynaecology, Paediatrics, Pain Management, Neurology, E&T, Oncology, Diabetes, Vascular Diseases and Veterinary Medicine.

All the above Micro-fine Sprays employ Disruptive, New, Patented Delivery Technology which treat symptoms in seconds, setting a new Gold Standard for treating skin conditions.

www.francemedpharma.com details our product portfolio

More Less

Product category: Universal medical commodities

Visit www.francemedpharma.com for a full products catalogue and corporate video

Visit www.francemedpharma.com for a full products catalogue and corporate video

More Less

Company news

Date

Topic

Download

Oct 27, 2017

Disruptive Patented Micro-fine Sprays that Treat Topical Symptoms in Seconds, Setting a new Gold Standard for treating Skin Conditions

FranceMed Pharma with its solid base in the British Market since 1981 and NHS reimbursable listings, owns Market Leading Ethical/OTC brands with unique attributes and is active in Class IIa Therapeutic Medical Devices: Discovery /R&D /Synthesis /Screening /Pre-Clinical /Clinical Phase I, II & III Studies / Marketing /Sales and Global Out-licensing. Its patented micro-fine sprays are classified as Discovery/Greenfield with No Competition, No Me-Toos and No Generics. The various sprays are clinically proven to treat prevalent conditions in Dermatology, Paediatrics, Gynaecology, Ophthalmology, First Aid and Veterinary. The unique disruptive micro-fine sprays treat within seconds mild to severe itch, pain, swelling, burning, stinging and repetitive use results in treating the underlying condition.

The unique, patented, Discovery/On The Market OTC micro-fine sprays employ the proprietary disruptive ‘Instant T-CNS Signalling System”™ delivery technology to instantly treat mild to severe conditions related to the above therapeutic areas, with no known side effects. Such conditions normally require high strength steroids, antihistamines or complex lengthy procedures which the new patented delivery technology ‘Instant T-CNS Signalling System”™ effectively replaces, setting a new Gold Standard for treating skin conditions.

FranceMed Pharma unique “Instant T-CNS Signalling System”™ new delivery technology allows a number of stimuli: Thermal (Cooling), Mechanical (triggers Melzack Gate Theory) and Chemical (Synthesis) to be applied topically and simultaneously on the affected areas achieving instant results and greater efficacy than when applying each stimulus in turn. Such stimuli, acting collectively, are a powerful therapeutic tool, as millions of signals are communicated to the CNS via neurotransmitters which instantly trigger the effective treatment of the symptoms and underlying conditions, through repetitive use.
For example, the Dermatological micro-fine sprays for adults and children are clinically proven to safely replace the need for steroids, antihistamines, emollients, pain killers and calamine lotion collectively, resulting in safer, faster, more effective, convenient and more economical treatment for the patient.

The micro-fine topical sprays ease of use, without touching the affected area and ability to treat large areas of the skin in one swoop resulted in excellent patient compliance. There are no known side effects, whether in the pre-market clinical studies phase or in the post-market phase, when millions of packs were used by patients.

The branded finished products, will be on display in Hall16 F20-2 and are available for Out-Licensing /Distribution. FranceMed Pharma, the manufacturer and owner of the relevant patents and manufacturing know-how, plans to grant distribution rights to suitable distributors in several countries.

FranceMed Pharma, BCM France House, London WC1N 3XX

Contact: Mark Taylor
Info@francemedpharma.com       Tel: +44 (0) 20 8645 0773

More Less

About us

Company details


 FranceMed Pharma with its solid base in the British Market since 1981 and NHS reimbursable listings, owns patented Market Leading Ethical/OTC brands with unique attributes and is active in: Discovery /R&D /Synthesis /Screening /Pre-Clinical /Clinical Phase I, II & III Studies / Marketing /Sales and Global Out-licensing.

Its patented micro-fine sprays are classified as Discovery/Greenfield with No Competition, No Me-Toos and No Generics. The various products treat conditions in Dermatology, Paediatrics, Gynaecology, Ophthalmology, Pain Management, Neurology, E&T, Oncology, Diabetes, Vascular Diseases, First Aid and Veterinary Medicine.

Privately owned FranceMed operates with strong Balance Sheet and No Debt.

We offer:

A Unique Range of Therapeutic Micro-fine Sprays Employing our Disruptive Patented New Delivery Technology “Instant T-CNS Signalling System”™ (see video link below).

The micro-fine sprays have the following unique attributes:

1) Unique Discovery/Greenfield Medical Devices, no competition, no me-toos, no generics. 2) Disruptive Technology. 3) Patented. 4) Instant treatment of mild to severe cutaneous symptoms including itch, pain, stinging, burning, weals, swelling. 5) Repetitive use results in the treatment of the underlying conditions causing the symptoms. 6) Captures both the Ethical and OTC Markets. 7) Safe for all ages including children from birth and pregnant women.
8) Therapeutic Class IIa medical device, hence faster, simpler registration process while avoiding the drugs price fixing in some countries. 9) High patient compliance as majority of patients find the micro-fine sprays easy and quick to apply on large skin area.
10) Clinically proven with no side effects. 11) Satisfaction rate among doctors and patients is high. 12) Word of mouth and repeat purchase are phenomenal. 13) Manufactured in the UK, France and Germany. FranceMed owns the Manufacturing know-how. 

One spray application collectively replaces: steroids, antihistamines, emollients, painkiller and calamine lotion with no side effects, setting a new gold standard for treating skin conditions.

Link for Corporate Video: http://www.francemedpharma.com/new-delivery-technology.html

FranceMed Therapeutic Categories: Dermatology(7 SKUs) , Paediatrics (9 SKUs), Gynaecology(4 SKUs), Emergency Medicine (3 SKUs), Veterinary (1 SKU). Products in other therapeutic areas are due to leave the pipeline shortly.

Major Distributors are sought with solid experience in one or more of the above specialties and who are market leaders in their countries.

Collaborators: Big Pharma and reputable distributors in several markets in Europe, Asia and the Middle East.

We are interested in:

Distribution or In-licensing deals with established Distributors who employ Medical/Sales reps to promote and market new products in their territories.

Collaboration based on Transfer Prices or In-Licensing are considered.

More Less

Company data

Number of employees

50-99

Foundation

1981

Area of business

Commodities and Consumer Good for Surgeries and Hospitals